July 19, 2018 / 12:09 PM / 3 months ago

BRIEF-Allergan And Molecular Partners Announce Two Positive Phase 3 Clinical Trials

July 19 (Reuters) - Allergan Plc:

* ALLERGAN AND MOLECULAR PARTNERS ANNOUNCE TWO POSITIVE PHASE 3 CLINICAL TRIALS FOR ABICIPAR PEGOL 8 AND 12-WEEK REGIMENS FOR THE TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

* ALLERGAN - TWO PIVOTAL HEAD-TO-HEAD TRIALS DEMONSTRATE EFFICACY OF ABICIPAR 12-WEEK FIXED DOSING REGIMEN WITH 50 PERCENT FEWER INJECTIONS VERSUS RANIBIZUMAB

* FILING FOR ABICIPAR IS PLANNED FOR FIRST HALF OF 2019

* ALLERGAN - ABICIPAR, ACHIEVED PRIMARY ENDPOINT OF NON-INFERIORITY TO MONTHLY RANIBIZUMAB AT WEEK 52 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below